Aspira Women's Health Wins Laboratory Service Contract with University of Texas Medical Branch at Galveston
Aspira Women's Health (NASDAQ:AWHL) executed a new 12-month laboratory services agreement with University of Texas Medical Branch at Galveston (UTMB Galveston) announced October 29, 2025. The contract is part of Aspira's redefined marketing strategy to prioritize larger organizations that enable efficient access to thousands of potential patients and care providers per platform adoption.
The agreement is intended to expand patient access for Aspira's Ova1Plus® and OvaWatch® diagnostics in the Texas market and to accelerate revenue growth by leveraging technology and strategic relationships.
Aspira Women's Health (NASDAQ:AWHL) ha stipulato un nuovo contratto di servizi di laboratorio di 12 mesi con l'Università del Texas Medical Branch a Galveston (UTMB Galveston), annunciato il 29 ottobre 2025. Il contratto fa parte della nuova strategia di marketing di Aspira, che dà priorità a organizzazioni più grandi che consentono un accesso efficiente a migliaia di potenziali pazienti e fornitori di assistenza per l'adozione della piattaforma.
Il contratto è volto ad espandere l'accesso dei pazienti ai diagnostici Ova1Plus® e OvaWatch® di Aspira nel mercato del Texas e ad accelerare la crescita dei ricavi sfruttando la tecnologia e le relazioni strategiche.
Aspira Women's Health (NASDAQ:AWHL) ejecutó un nuevo acuerdo de servicios de laboratorio de 12 meses con la University of Texas Medical Branch en Galveston (UTMB Galveston) anunciado el 29 de octubre de 2025. El contrato forma parte de la redefinida estrategia de marketing de Aspira para priorizar organizaciones más grandes que permiten un acceso eficiente a miles de pacientes potenciales y proveedores de atención por adopción de la plataforma.
El acuerdo tiene como objetivo ampliar el acceso de los pacientes a los diagnósticos Ova1Plus® y OvaWatch® de Aspira en el mercado de Texas y acelerar el crecimiento de ingresos aprovechando la tecnología y las relaciones estratégicas.
Aspira Women's Health (NASDAQ:AWHL)는 UTMB Galveston(University of Texas Medical Branch at Galveston)와 12개월 간의 실험실 서비스 계약을 새로 체결했다고 2025년 10월 29일에 발표했습니다. 이 계약은 더 큰 조직에 우선순위를 두고 플랫폼 채택당 수천 명의 잠재 환자와 케어 제공자에 효율적으로 접근할 수 있도록 하는 Aspira의 재정의된 마케팅 전략의 일부입니다.
계약의 목적은 텍사스 주 시장에서 Aspira의 Ova1Plus® 및 OvaWatch® 진단의 환자 접근성을 확대하고 기술과 전략적 관계를 활용하여 수익 성장을 가속화하는 것입니다.
Aspira Women's Health (NASDAQ:AWHL) a conclu un nouvel accord de services de laboratoire de 12 mois avec l'University of Texas Medical Branch à Galveston (UTMB Galveston) annoncé le 29 octobre 2025. Le contrat fait partie de la stratégie de marketing redéfinie d'Aspira visant à privilégier les organisations plus importantes qui permettent un accès efficace à des milliers de patients potentiels et de fournisseurs de soins par adoption de la plateforme.
L'accord vise à élargir l'accès des patients aux diagnostics Ova1Plus® et OvaWatch® d'Aspira sur le marché du Texas et à accélérer la croissance des revenus en tirant parti de la technologie et des relations stratégiques.
Aspira Women's Health (NASDAQ:AWHL) hat am 29. Oktober 2025 eine neue 12-monatige Vereinbarung über Laborleistungen mit der University of Texas Medical Branch in Galveston (UTMB Galveston) bekannt gegeben. Der Vertrag ist Teil von Aspiras neu definierter Marketingstrategie, größere Organisationen zu priorisieren, die einen effizienten Zugang zu Tausenden potenzieller Patienten und Pflegeanbieter pro Plattform- Adoption ermöglichen.
Ziel der Vereinbarung ist es, den Patientenzugang zu Aspiras Diagnostika Ova1Plus® und OvaWatch® im texanischen Markt zu erweitern und das Umsatzwachstum durch den Einsatz von Technologie und strategischen Beziehungen zu beschleunigen.
Aspira Women's Health (NASDAQ:AWHL) نفذت اتفاقية خدمات مختبرات جديدة لمدة 12 شهرًا مع قسم كلية الطب بجامعة تكساس في جالفستون (UTMB Galveston) كما أعلنت في 29 أكتوبر 2025. العقد جزء من استراتيجية Aspira المعاد تعريفها للتسويق والتي تركز على المؤسسات الأكبر التي تتيح وصولاً فعالاً إلى الآلاف من المرضى المحتملين ومقدمي الرعاية per اعتماد المنصة.
تهدف الاتفاقية إلى توسيع وصول المرضى إلى تشخيصات Ova1Plus® و OvaWatch® من Aspira في سوق تكساس ولدفع نمو الإيرادات من خلال الاستفادة من التكنولوجيا والعلاقات الاستراتيجية.
Aspira Women's Health (NASDAQ:AWHL) 与德克萨斯大学玛格斯坦分校健康研究院（UTMB Galveston）签署了一份为期 12 个月的实验室服务协议，于 2025 年 10 月 29 日宣布。该合同是 Aspira 重新定义的营销策略的一部分，旨在优先考虑能够通过平台采用实现对成千上万潜在患者与护理提供者高效访问的大型组织。
该协议旨在在德克萨斯州市场扩大 Aspira 的 Ova1Plus® 与 OvaWatch® 诊断的患者访问，并通过利用技术和战略关系来推动收入增长。
- Signed 12-month lab services agreement with UTMB Galveston (Oct 29, 2025)
- Expanded Texas reach for Ova1Plus and OvaWatch to a large market
- Go-to-market focus on large organizations to reach thousands of patients
- None.
Aspira Executes New, Scalable Laboratory Services Agreement in One of the Largest Markets in the US
AUSTIN, TX AND WASHINGTON, DC / ACCESS Newswire / October 29, 2025 / Aspira Women's Health Inc., abio-analytical-based women's health company focused on gynecologic disease diagnostics, today announced it has executed a new laboratory services agreement with University of Texas Medical Branch at Galveston ("UTMB Galveston"), a part of the University of Texas System.
The initial term of the agreement is 12 months and is part of the Company's redefined marketing strategy that has prioritized marketing the Company's health care solutions to larger organizations that enable Aspira to efficiently reach thousands of potential patients and their care providers with each new platform adoption. With this new lab services agreement the Company has taken meaningful steps to reach new patients in the Texas market for its Ova1Plus® and OvaWatch® products.
"I am pleased to announce such a prestigious new client addition on behalf of our team," commented Mike Buhle, CEO of Aspira. "One of our top priorities has been to transform and improve our go-to-market strategy. We are extremely focused on growing our Ova1Plus® and OvaWatch® revenues in the most efficient, accelerated way possible. Our partnership with University of Texas Medical Branch at Galveston is an excellent example of how we aim to quickly leverage technology and strategic relationships to reach more patients and positively impact women's health."
About Aspira Women's Health Inc.
Aspira Women's Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases. OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer risk for the 1.2+ million American women diagnosed with an adnexal mass each year.
OvaWatch provides a negative predictive value of
Our in-development test pipeline will expand our ovarian cancer portfolio and address the tremendous need for non-invasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, we intend to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, we have developed the first-ever non-invasive test designed to identify endometriomas, one of the most commonly occurring forms of severe endometriosis. Through our ongoing endometriosis development program, we are combining microRNA and protein biomarkers with patient data, with the intent of identifying all endometriosis independent of disease location or severity.
Forward-Looking Statements
This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve a number of risks and uncertainties. Such forward-looking statements include statements regarding, among other things, the timing and completion of any products in the development pipeline and other statements that are predictive in nature, and whether the marketing of the OvaSuite portfolio will prove successful. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "designed to," "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," and other words of similar meaning and the use of future dates. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission (SEC), including those factors identified as "Risk Factors" in our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Aspira presently does not know, or that Aspira currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Aspira's expectations, plans, or forecasts of future events and views as of the date of this press release. Subsequent events and developments may cause the Company's assessments to change. However, while Aspira may elect to update these forward-looking statements at some point in the future, Aspira expressly disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Aspira's assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Investor Relations Contact:
investors@aspirawh.com
SOURCE: Aspira Women's Health
View the original press release on ACCESS Newswire
FAQ
What did Aspira announce on October 29, 2025 regarding UTMB Galveston (AWHL)?
How will the UTMB Galveston agreement affect Aspira's Ova1Plus and OvaWatch (AWHL)?
What is the term length of the Aspira and UTMB Galveston agreement (AWHL)?
Why is Aspira targeting larger organizations with its marketing strategy (AWHL)?
Does the UTMB Galveston contract include financial details for Aspira (AWHL)?
When was Aspira's partnership with UTMB Galveston announced (AWHL)?
